Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

The Bayer Activities of Daily Living Scale (B-ADL)

Hindmarch I.a · Lehfeld H.b · de Jongh P.c · Erzigkeit H.b

Author affiliations

a Human Psychopharmacology Research Unit, University of Surrey, UK; b Psychiatric University Hospital Erlangen, c Bayer AG, Leverkusen, Germany

Related Articles for ""

Dement Geriatr Cogn Disord 1998;9(suppl 2):20–26

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: July 15, 1998
Issue release date: July 1998

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM

Abstract

The Bayer Activities of Daily Living Scale (B-ADL) has been developed on an international basis to assess deficits in the performance of everyday activities. The scale’s main target group is community dwelling patients who suffer mild cognitive impairment or mild-to-moderate dementia. It comprises 25 items and takes the form of a questionnaire to be completed by a caregiver or other informant sufficiently familiar with the patient. Statistical, clinical and domain-related criteria were used to select items from among a large number of activities of daily living (ADL) questions field tested in pilot studies in the USA, Germany, UK, Russia and Greece. The items included in the B-ADL have been chosen for their sensitivity to cognitive impairment, simplicity of concept, international applicability and their relevance to patients coping with the demands of everyday life. The scale uses items which reflect a wide range of domains. On account of its brevity, it is thought especially suitable for application within a GP and primary care context for both screening a patient’s ADL capacities as well as for documentation of treatment effects and the progress of dementia. This paper focuses on a description of the scale and its application.


References

  1. Rubin EH, Morris C, Grant EA, Vendegna T: Very mild senile dementia of the Alzheimer type. I: Clinical assessment. Arch Neurology 1989;46:379–382.
    External Resources
  2. Morris JC, McKeel DW, Storandt M, Rubin EH, Price JL, Grant EA, Ball MJ, Berg L: Very mild Alzheimer’s disease: Informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology 1991;41:469–478.
  3. Curran S, Russell E, Burns A: Treatment of cognitive deficits in Alzheimer’s disease. Prim Care Psychiatry 1997;3,151–161.
  4. Jorm AF, Korten AE: Assessment of cognitive decline in the elderly by informant interview. Br J Psych 1988;152:209–213.
  5. Committee for Proprietary Medicinal Products (CPMP): Note for guidance on medicinal products in the treatment of Alzheimer’s disease. The European Agency for the Evaluation of Medicinal Products. London, Human Medicines Evaluation Unit, 1997.
  6. Gauthier S, Bodick N, Erzigkeit H, Feldman H, Geldmacher DS, Huff J, Mohs R, Orgogozo JM, Rogers S: Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11(suppl 3):6–7.
  7. Leber P: Guidelines for the clinical evaluation of antidementia drugs. First draft. Rockville, Food and Drug Administration, 1990.
  8. Clinical Research Working Group from the Pharmaceutical Industry on Dementia: Recommendations for clinical drug trials in dementia. Dementia 1990;1:292–295.
  9. Poon LW: On the paradox of improving sensitivity of ADL scales for the detection of behavioural changes in early dementia. Int Psychogeriatr 1994;6:171–177.
  10. Schmidt-Gollas N, Erzigkeit H: Ways of constructing a therapy sensitive scale for the assessment of ADL aspects in cognitively impaired elderly patients; in Bergener M, Belmaker R, Tropper H (eds): Pharmacotherapy for the elderly. Research and Implications. New York, Springer, 1993, pp 119–131.
  11. Erzigkeit H, Overall JE, Stemmler M, Steinwachs KC, Lehfeld H, Hulla FW: Assessing behavioral changes in antidementia therapy: Perspectives of an international ADL-project; in Bergener M, Brocklehurst J, Finkel S (eds): Aging, Health, and Healing. New York, Springer, 1995, pp 359–374.
  12. Finkel S, Bergener M, Stemmler M, Hulla F, Overall JE: The use of clinical experience to stage the severity of functional impairments in Alzheimer’s disease. Hum Psychopharmacol 1996;11:439–449.
    External Resources
  13. Lehfeld H, Reisberg B, Finkel S, Kanowski S, Wied V, Pittas J, Tsolaki M, Robert PH, Hulla F, Heininger K, Erzigkeit H: Informant-rated Activities-of-Daily-Living (ADL) Assessments: Results of a study of 141 items in the USA, Germany, Russia, and Greece from the International ADL Scale Development Project. Alzheimer Dis Assoc Disord 1997;11(suppl 4): S39–S44.
  14. Reisberg B: The ADL-IS: History and Progress. Presentation at the eighth congress of the International Psychogeriatric Association (IPA). 1996, Jerusalem, Israel, August 17–22.
  15. Barberger-Gateau P, Commenges D, Gagnon M, Letenneur L, Sauvel C, Dartigues JF: Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers. J Am Geriatr Soc 1992;40:1129–1134.
  16. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S, Alzheimer’s Disease Cooperative Study: An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. Alzheimer Dis Assoc Disord;11(suppl 2):S33–S39.
  17. Lundin-Olsson l, Nyberg L, Gustafson Y: ‘Stops walking when talking’ as a predictor of falls in elderly people. Lancet 1997, 349:617.
  18. Herberg KW, Steinwachs KC, Woelk H, Bernhardt T: Alltagskompetenz älterer Patienten wächst unter einer Therapie mit Nimodipin. Extracta Geriatrica 1997;3:20–25.
  19. Heininger K, Keppel Hesselink JM: The role of the Bayer ADL-International Scale in the management of dementia patients. Presentation at the eighth congress of the International Psychogeriatric Association (IPA). 1996, Jerusalem, Israel, August 17–22.
  20. Brislin RW: The wording and translation of research instruments; in Lonner W, Berry J (eds): Field methods in Cross-Cultural Research. Beverly Hills, Sage, 1986, pp 137–164.
  21. Sartorius N, Kuyken W: Translation of health status instruments; in Orley J, Kuyken W (eds): Quality of Life Assessment in Health Care Settings. Berlin, Springer, 1994, pp 3–18.
  22. Reisberg B, Ferris SH, deLeon MJ, Crook T: The Global Deterioration Scale for the assessment of primary degenerative dementia. Am J Psych 1982;139:1136–1139.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: July 15, 1998
Issue release date: July 1998

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.